AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14610443 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving a videotape on the importance of reading
Number of subjects: 165
Study 10518845 — intervention group
Group type: COMPARATOR
Intervention: Budesonide inhalation suspension
Number of subjects: 0
Study 7488804 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged emptying of one breast at each feed (experimental group)
Number of subjects: 302
Study 7488804 — intervention group
Group type: COMPARATOR
Intervention: Both breasts equally drained at each feed (control group)
Number of subjects: 302
Study 1834598 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% metronidazole and 5% benzoyl peroxide cream
Number of subjects: 4
Study 7048920 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir (200 mg five times a day for five days)
Number of subjects: 90
Study 31202211 — intervention group
Group type: EXPERIMENTAL
Intervention: Fib-19-01
Number of subjects: 100
Study 31202211 — intervention group
Group type: COMPARATOR
Intervention: Food Supplement (FS)
Number of subjects: 100
Study 31202211 — intervention group
Group type: COMPARATOR
Intervention: No Supplementary Treatment (NoST)
Number of subjects: 100
Study 30465349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting with 50 µm alumina oxide at 0.2 MPa pressure
Number of subjects: 63
Study 30465349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting with 50 µm alumina oxide at 0.4 MPa pressure
Number of subjects: 63
Study 30465349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting with 50 µm alumina oxide at 0.6 MPa pressure
Number of subjects: 63
Study 30465349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting with 100 µm alumina oxide at 0.2 MPa pressure
Number of subjects: 63
Study 30465349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandblasting with 100 µm alumina oxide at 0.4 MPa pressure
Number of subjects: 63
Study 26545141 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone 2mg/kg loading dose followed by 1mg/kg/day continuous infusion from days 1 to 7
Number of subjects: 35
Study 26545141 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 24793711 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL of 1.5% mepivacaine solution (n=31)
Number of subjects: 64
Study 24793711 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mL of 1.5% mepivacaine solution (n=33)
Number of subjects: 64
Study 22325367 — intervention group
Group type: EXPERIMENTAL
Intervention: EnSite NavX™ mapping system
Number of subjects: 210
Study 22325367 — intervention group
Group type: COMPARATOR
Intervention: Conventional catheter ablation
Number of subjects: 210
Study 19631515 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein aglycone (54mg daily)
Number of subjects: 138
Study 19631515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study 19631515 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein aglycone
Number of subjects: 138
Study 18538112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin/metformin fixed-dose combination tablets (50/500 mg)
Number of subjects: 0
Study 18538112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin/metformin fixed-dose combination tablets (50/850 mg)
Number of subjects: 0
Study 18538112 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin/metformin fixed-dose combination tablets (50/1,000 mg)
Number of subjects: 0
Study 18538112 — intervention group
Group type: COMPARATOR
Intervention: Vildagliptin/metformin fixed-dose combination tablets
Number of subjects: 0
Study 16009687 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency thermal ablation (RFTA)
Number of subjects: 187
Study 16009687 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous ethanol injection (PEI)
Number of subjects: 187
Study 16009687 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous acetic acid injection (PAI)
Number of subjects: 187
Study 12296618 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human activated protein C (Xigris®)
Number of subjects: 0
Study 12296618 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 10604045 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac free acid suspension (50 mg)
Number of subjects: 24
Study 7561229 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia
Number of subjects: 32
Study 7561229 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic relaxation
Number of subjects: 32
Study 7561229 — intervention group
Group type: COMPARATOR
Intervention: Control group (suggestion alone, hypnotic induction plus suggestion)
Number of subjects: 32
Study 1948378 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol/alfentanil anesthesia
Number of subjects: 20
Study 1948378 — intervention group
Group type: COMPARATOR
Intervention: Nitrous oxide/alfentanil anesthesia
Number of subjects: 20
Study 1948378 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pass digital filtering (30-Hz)
Number of subjects: 20
Study 1948378 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective study
Number of subjects: 20
Study 6764119 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole hydrochloride (150 mg daily for 3 consecutive days every fortnight)
Number of subjects: 50
Study 6764119 — intervention group
Group type: COMPARATOR
Intervention: Control group (no further treatment until progressive disease)
Number of subjects: 50
Study 31981236 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain severity assessed during walking using the Western Ontario and McMasters Universities Osteoarthritis Index (no pain = 10; mild pain = 28; moderate pain = 17)
Number of subjects: 55
Study 31981236 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiographic disease severity graded by Kellgren and Lawrence scale (KL2 = 29; KL3 = 21; KL4 = 5)
Number of subjects: 55
Study 31981236 — intervention group
Group type: EXPERIMENTAL
Intervention: Coordination variability for select joint couplings
Number of subjects: 55
Study 31654592 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 80
Study 31654592 — intervention group
Group type: COMPARATOR
Intervention: Control (no DSWI)
Number of subjects: 80
Study 28678148 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (No-L-group)
Number of subjects: 94
Study 28678148 — intervention group
Group type: COMPARATOR
Intervention: No levosimendan (L-group)
Number of subjects: 94
Study 26498398 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-lasting cerebral vasospasm (LL-CVS) treatment
Number of subjects: 106
Study 26498398 — intervention group
Group type: COMPARATOR
Intervention: Regular-lasting cerebral vasospasm (control group)
Number of subjects: 106
Study 24486425 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA tDCS + CCT
Number of subjects: 27
Study 24486425 — intervention group
Group type: COMPARATOR
Intervention: sham tDCS + CCT
Number of subjects: 27
Study 24486425 — intervention group
Group type: COMPARATOR
Intervention: sham CCT + 2 mA tDCS
Number of subjects: 27
Study 21892676 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised weight-bearing jumping exercises and circuit training
Number of subjects: 498
Study 21892676 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 498
Study 19550337 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 microg kg(‐1)) infusion
Number of subjects: 30
Study 19550337 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1.0 microg kg(‐1)) infusion
Number of subjects: 30
Study 17559746 — intervention group
Group type: EXPERIMENTAL
Intervention: Terlipressin
Number of subjects: 0
Study 17559746 — intervention group
Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 0
Study 17559746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16255132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin) as a component of first-line treatment
Number of subjects: 0
Study 16255132 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing bevacizumab in subsequent regimens
Number of subjects: 0
Study 16255132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (Erbitux) in standard first-line chemotherapy
Number of subjects: 0
Study 16255132 — intervention group
Group type: EXPERIMENTAL
Intervention: Widely accepted practices in colorectal cancer without direct supportive data
Number of subjects: 0
Study 12372195 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-invasive continuous positive airways pressure (CPAP) for 18 hours
Number of subjects: 25
Study 12372195 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (nebulized epinephrine and humidified oxygen)
Number of subjects: 25
Study 10334519 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorouracil (FU) + Folinic acid (Leucovorin, LV)
Number of subjects: 1016
Study 10334519 — intervention group
Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 1016
Study 1433587 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 434
Study 1433587 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 434
Study 3894245 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (Prednisolone 1 mg/kg/day for 9 days over 3 cycles)
Number of subjects: 10
Study 3894245 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3894245 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid therapy (Prednisolone)
Number of subjects: 10
Study 31356713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior therapy (CBT)
Number of subjects: 319
Study 31356713 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 319
Study 31356713 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + medication
Number of subjects: 319
Study 31356713 — intervention group
Group type: COMPARATOR
Intervention: Pill placebo
Number of subjects: 319
Study 31356713 — intervention group
Group type: EXPERIMENTAL
Intervention: CAMS remission
Number of subjects: 319
Study 31356713 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment response and remission
Number of subjects: 319
Study 31356713 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline self-reported depressive symptoms
Number of subjects: 319
Study 31356713 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative life events
Number of subjects: 319
Study 28953199 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of hemodynamic information for heart failure management decisions
Number of subjects: 550
Study 28953199 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery pressure monitoring system
Number of subjects: 550
Study 28953199 — intervention group
Group type: COMPARATOR
Intervention: Control group (no hemodynamic information available)
Number of subjects: 550
Study 26725133 — intervention group
Group type: EXPERIMENTAL
Intervention: MICA-TKA
Number of subjects: 108
Study 26725133 — intervention group
Group type: COMPARATOR
Intervention: Conventional TKA
Number of subjects: 108
Study 26335706 — intervention group
Group type: EXPERIMENTAL
Intervention: Palonosetron (0.075 mg i.v.; n = 35)
Number of subjects: 105
Study 26335706 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron (3 mg i.v.; n = 35)
Number of subjects: 105
Study 26335706 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramosetron (0.3 mg i.v.; n = 35)
Number of subjects: 105
Study 26335706 — intervention group
Group type: COMPARATOR
Intervention: Overall incidence of PONV
Number of subjects: 105
Study 26335706 — intervention group
Group type: COMPARATOR
Intervention: Statistical difference in complete responders
Number of subjects: 105
Study 24156441 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple mobilization group (5.0‐10.0 µg/(kg·d) rhG‐CSF)
Number of subjects: 43
Study 24156441 — intervention group
Group type: COMPARATOR
Intervention: Combined mobilization group (rhG‐CSF + 10 mg dexamethasone for 2‐4 hours before collection)
Number of subjects: 43
Study 21372623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 6 weekly 90-min sessions
Number of subjects: 182
Study 21372623 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (Control)
Number of subjects: 182
Study 21372623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 182
Study 18323548 — intervention group
Group type: COMPARATOR
Intervention: Exemestane 25 mg daily
Number of subjects: 111
Study 18323548 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of exemestane 25 mg daily with celecoxib 400 mg twice daily
Number of subjects: 111
Study 18323548 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of exemestane and celecoxib
Number of subjects: 111
Study 16580574 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium and CLA supplementation
Number of subjects: 48
Study 16580574 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 14521724 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y technique (RY)
Number of subjects: 149
Study 14521724 — intervention group
Group type: COMPARATOR
Intervention: P pouch with Roux-en-Y reconstruction (PRY)
Number of subjects: 149
Study 14521724 — intervention group
Group type: COMPARATOR
Intervention: Jejunal pouch reconstruction according to Hunt-Lawrence technique (HL)
Number of subjects: 149
Study 14521724 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunal pouch original interposition reconstruction (JOP)
Number of subjects: 149
Study 14521724 — intervention group
Group type: EXPERIMENTAL
Intervention: Hunt-Lawrence reconstruction technique maintaining duodenal passage (HLD)
Number of subjects: 149
Study 10741936 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 600 mg/day
Number of subjects: 54
Study 10741936 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 1200 mg/day
Number of subjects: 54
Study 10741936 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 2400 mg/day
Number of subjects: 54
Study 10741936 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 54
Study 9385176 — intervention group
Group type: EXPERIMENTAL
Intervention: Emollient antibacterial soap
Number of subjects: 84
Study 9385176 — intervention group
Group type: COMPARATOR
Intervention: Non-emollient antibacterial soap
Number of subjects: 84
Study 7714353 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin added to standard MDT
Number of subjects: 20
Study 7714353 — intervention group
Group type: COMPARATOR
Intervention: Standard MDT alone
Number of subjects: 20
Study 3592139 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisolone 7.5 mg daily for 3 weeks
Number of subjects: 36
Study 3592139 — intervention group
Group type: COMPARATOR
Intervention: Injection with 2 ml suspension of betamethasone dipropionate and betamethasone disodium phosphate (Diprospan)
Number of subjects: 36
Study 31072189 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-treatment response adaptive procedure
Number of subjects: 0
Study 31072189 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-adaptive randomization (RAR)
Number of subjects: 0
Study 31072189 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative odds ratios
Number of subjects: 0
Study 29402879 — intervention group
Group type: EXPERIMENTAL
Intervention: HF‐rTMS + TOMT
Number of subjects: 20
Study 29402879 — intervention group
Group type: COMPARATOR
Intervention: HF‐rTMS
Number of subjects: 20
Study 26673107 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived high cholesterol as 'very serious'
Number of subjects: 155
Study 26673107 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-efficacy
Number of subjects: 155
Study 24638238 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose-rate (HDR) brachytherapy
Number of subjects: 652
Study 24638238 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose-rate (LDR) brachytherapy
Number of subjects: 652
Study 23785909 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented repair
Number of subjects: 0
Study 23785909 — intervention group
Group type: COMPARATOR
Intervention: Non-augmented repair
Number of subjects: 0
Study 20156091 — intervention group
Group type: EXPERIMENTAL
Intervention: EFV/FTC/TDF
Number of subjects: 300
Study 20156091 — intervention group
Group type: COMPARATOR
Intervention: SBR
Number of subjects: 300
Study 18071815 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 257
Study 18071815 — intervention group
Group type: COMPARATOR
Intervention: Small-incision cholecystectomy (SIC)
Number of subjects: 257
Study 18071815 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal invasive procedures (LC and SIC combined)
Number of subjects: 257
Study 18071815 — intervention group
Group type: COMPARATOR
Intervention: Converted procedures (non-minimal invasive)
Number of subjects: 257
Study 16368847 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver with peak inspiratory pressures up to 50 cm H2O followed by ventilation with 12 cm H2O PEEP
Number of subjects: 0
Study 16368847 — intervention group
Group type: COMPARATOR
Intervention: Standard ventilation with 4 cm H2O PEEP (Control)
Number of subjects: 0
Study 16368847 — intervention group
Group type: EXPERIMENTAL
Intervention: Alveolar recruitment maneuver
Number of subjects: 0
Study 12972958 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonic J-pouch
Number of subjects: 40
Study 12972958 — intervention group
Group type: COMPARATOR
Intervention: Coloplasty pouch
Number of subjects: 40
Study 10380294 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal heart rate variability in diabetic women
Number of subjects: 16
Study 10380294 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical artery peak systolic velocity in diabetic women
Number of subjects: 16
Study 10380294 — intervention group
Group type: COMPARATOR
Intervention: Fetal heart rate and umbilical artery time-averaged velocity
Number of subjects: 16
Study 10380294 — intervention group
Group type: COMPARATOR
Intervention: Variability in umbilical artery flow velocity
Number of subjects: 16
Study 8829857 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg.ml‐1 of morphine and ketamine (n = 22)
Number of subjects: 42
Study 8829857 — intervention group
Group type: COMPARATOR
Intervention: 1 mg.ml‐1 of morphine (n = 20)
Number of subjects: 42
Study 1729575 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate orally four times a day during hospitalization
Number of subjects: 95
Study 1729575 — intervention group
Group type: COMPARATOR
Intervention: No iron supplement (Control group)
Number of subjects: 95
Study 6727693 — intervention group
Group type: EXPERIMENTAL
Intervention: High oestrogen dose (oestriol and 17 beta‐oestradiol)
Number of subjects: 177
Study 6727693 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium oestrogen dose (oestriol and 17 beta‐oestradiol)
Number of subjects: 177
Study 6727693 — intervention group
Group type: EXPERIMENTAL
Intervention: Low oestrogen dose (oestriol and 17 beta‐oestradiol)
Number of subjects: 177
Study 6727693 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 177
Study 6727693 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of oestrogens
Number of subjects: 177
Study 31128325 — intervention group
Group type: EXPERIMENTAL
Intervention: TBF conditioning regimen (thiotepa, busulfan, and fludarabine) with post-transplant cyclophosphamide (PT-Cy)
Number of subjects: 100
Study 30054636 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive CTC assay result (at least 1 CTC per 7.5 mL of blood)
Number of subjects: 547
Study 30054636 — intervention group
Group type: EXPERIMENTAL
Intervention: CTC-positive group
Number of subjects: 547
Study 30054636 — intervention group
Group type: COMPARATOR
Intervention: CTC-negative group
Number of subjects: 547
Study 30054636 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive CTC assay result
Number of subjects: 547
Study 30054636 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive CTC assay result in hormone receptor-negative disease
Number of subjects: 547
Study 26908305 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged release (PR) oxycodone with naloxone
Number of subjects: 0
Study 26908305 — intervention group
Group type: COMPARATOR
Intervention: Prolonged release (PR) oxycodone
Number of subjects: 0
Study 25145426 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Number of subjects: 0
Study 25145426 — intervention group
Group type: COMPARATOR
Intervention: Traditional chemotherapy
Number of subjects: 0
Study 22209655 — intervention group
Group type: EXPERIMENTAL
Intervention: Awareness of positive HCV status
Number of subjects: 1281
Study 22209655 — intervention group
Group type: COMPARATOR
Intervention: Negative/unknown HCV status
Number of subjects: 1281
Study 20538020 — intervention group
Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 1318
Study 20538020 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-addicted smokers
Number of subjects: 1318
Study 20538020 — intervention group
Group type: COMPARATOR
Intervention: Never-smoking controls
Number of subjects: 1318
Study 17261429 — intervention group
Group type: COMPARATOR
Intervention: High-flux synthetic membranes
Number of subjects: 648
Study 17261429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulosic low-flux membranes
Number of subjects: 648
Study 17261429 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux semisynthetic membranes
Number of subjects: 648
Study 17261429 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux synthetic membranes
Number of subjects: 648
Study 17261429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulosic low-flux vs low-flux synthetic membranes
Number of subjects: 648
Study 17261429 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-flux semisynthetic vs low-flux synthetic membranes
Number of subjects: 648
Study 17261429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulosic low-flux vs low-flux semisynthetic membranes
Number of subjects: 648
Study 15872132 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (Group I, n = 15)
Number of subjects: 32
Study 15872132 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (Group S, n = 17)
Number of subjects: 32
Study 12093837 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided catheter moulding
Number of subjects: 640